Evogene (NASDAQ:EVGN) Coverage Initiated by Analysts at StockNews.com

Research analysts at StockNews.com started coverage on shares of Evogene (NASDAQ:EVGN) in a note issued to investors on Sunday. The brokerage set a “sell” rating on the biotechnology company’s stock.

Evogene Stock Down 2.1 %

Shares of NASDAQ:EVGN opened at $1.90 on Friday. The company has a market capitalization of $10.19 million, a price-to-earnings ratio of -0.43 and a beta of 1.30. The firm has a 50 day moving average of $1.70 and a 200 day moving average of $3.29. Evogene has a 52 week low of $1.20 and a 52 week high of $10.40.

Hedge Funds Weigh In On Evogene

A hedge fund recently bought a new stake in Evogene stock. Renaissance Investment Group LLC purchased a new position in shares of Evogene Ltd. (NASDAQ:EVGN) in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 10,000 shares of the biotechnology company’s stock, valued at approximately $31,000. Hedge funds and other institutional investors own 10.40% of the company’s stock.

Evogene Company Profile

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications.